Pfizer (NYSE:PFE) Trading Up 0.3%

Pfizer Inc. (NYSE:PFE) rose 0.3% during mid-day trading on Friday . The company traded as high as $27.88 and last traded at $27.81. Approximately 7,681,293 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 40,956,109 shares. The stock had previously closed at $27.74.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research analyst reports. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley increased their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Ten analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $35.86.

Pfizer Stock Performance

The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The firm’s 50-day moving average is $27.63 and its two-hundred day moving average is $27.73. The stock has a market cap of $156.74 billion, a P/E ratio of -463.42, a price-to-earnings-growth ratio of 1.08 and a beta of 0.70.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter last year, the company posted $1.23 earnings per share. The company’s revenue for the quarter was down 19.5% compared to the same quarter last year. As a group, research analysts expect that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 10th were issued a dividend of $0.42 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.07%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Hedge Funds Weigh In On Pfizer

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ironvine Capital Partners LLC grew its holdings in Pfizer by 2.1% in the 1st quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock valued at $470,000 after buying an additional 353 shares in the last quarter. Advisor OS LLC grew its holdings in Pfizer by 1.0% in the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after buying an additional 365 shares in the last quarter. Safeguard Investment Advisory Group LLC grew its holdings in Pfizer by 3.9% in the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after buying an additional 371 shares in the last quarter. Lantz Financial LLC grew its holdings in Pfizer by 1.3% in the 1st quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after buying an additional 381 shares in the last quarter. Finally, Wellington Shields Capital Management LLC grew its holdings in Pfizer by 1.3% in the 1st quarter. Wellington Shields Capital Management LLC now owns 30,750 shares of the biopharmaceutical company’s stock valued at $853,000 after buying an additional 385 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.